x

Posted 05 March, 2024

IR-Med, Inc. appointed Mr. Aharon Klein as new CEO

OTC:IRME appointed new Chief Executive Officer Mr. Aharon Klein in a 8-K filed on 05 March, 2024.


  Effective as of February 28, 2024, the board of directors (the "Board") of IR-Med, Inc. (the "Company") appointed Mr. Aharon Klein Chief Technology Officer and a cofounder of the company to serve as its Interim Chief Executive Officer as well as the Interim Chief Executive Officer of the Company's wholly-owned subsidiary, IR-Med LTD., an Israeli corporation.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of IR-Med, Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
IR-Med, Inc. is engaged in the designing and developing devices utilizing spectrographic usability medical devices based on the combination of Infra-Red (IR) and Artificial Intelligence (AI) technologies. The company was founded by Ronnie Klein and Yaniv Cohen in April 2007 and is headquartered in Rosh Haayin, Israel.
Market Cap
$101M
View Company Details
IR-Med, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 


Effective as of February 28, 2024, the board of directors (the "Board") of IR-Med, Inc. (the "Company") appointed Mr. Aharon Klein Chief Technology Officer and a cofounder of the company to serve as its Interim Chief Executive Officer as well as the Interim Chief Executive Officer of the Company's wholly-owned subsidiary, IR-Med LTD., an Israeli corporation.


Mr. Aharon Klein, age 60, co-founded IR. Med, Ltd in September 2013 and has served as a director of the Company since. He also served as the Company's Chief Operating Officer from September 2013 until December 2020. Since December 2020, Mr. Klein serves as the Company's Chief Technology Officer. Mr. Klein is a medical device and biotech expert, with a strong clinical background. Prior to founding the Company, from 2004 to 2007 Mr. Klein co-founded and served as Chief Executive Officer of Fertiligent, a start-up company focused on innovative fertility treatments, which was acquired by a United Kingdom based investment group in 2008. From 2008 to 2013, immediately prior to co-founding of the Company, he founded a medical device company developing infrared based diagnostic tools for diagnosing colon cancer without the need for biopsies (optical biopsies). Mr. Klein graduated from the Faculty of Engineering in the Technion - Israel Institute of Technology. Mr. Klein is experienced in initiating and running medical device start-up companies, including development running clinical trials and regulatory affairs.


Following Mr. Klein's appointment, he will continue to be employed by the Company under the same terms of his current service provider agreement with the Company.